FERRING PHARMACEUTICALS, INC.

REBYOTA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

FERRING PHARMACEUTICALS, INC.

Rebyota HCPCS:

J1440

HCPCS Code Descriptor:

Fecal microbiota, live - jslm, 1 ml

Category:

J Code

Rebyota NDCs:

55566-9800-02

Primary Type:

Fecal

Generic/Specialty Status:

Single-Source

Package Type:

Bag

Route of Administration:

Rectal

Rebyota CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

55566-9800-02

About Rebyota:

REBYOTA is a Fecal drug manufactured by FERRING PHARMACEUTICALS, INC. and administered via the Rectal route of administration. The J Code: J1440 is aligned to the drug REBYOTA.

Rebyota is a gastrointestinal agent that works by using healthy bacteria from stool. These healthy bacteria are used to treat CDI. Rebyota is the first microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) to prevent recurrence of CDI. This is used to help prevent a certain type of infection. Rebyota is aligned to the HPCS code J1440 and is not a generic medication that is manufactured by Ferring Pharmaceuticals. Patient assistance programs for this medication can be found through Rebyota’s website.

ACCESS PRICING AND MORE BY REGISTERING

J1440 Added Date:

July 1, 2023

J1440 Effective Date:

July 1, 2023

J1440 Termination Date:

HCPCS Active

Our team has not identified a manufacturer source of billing and coding information for REBYOTA
Rebyota patient assistance information can be found through Ferring Pharmaceuticals at the URL: https://www.rebyota.com/rebyota-support-resources/
REBYOTA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for REBYOTA. Please check back in a few weeks.